RegulatoryOfficial

MHRA to legislate on revised gene therapy definition after strong consultation support

🇬🇧 MHRA · Thu 19 Nov 2026

The MHRA and Northern Ireland's health department will pursue secondary legislation to update how gene therapy medicinal products are defined, after 83% of 48 respondents backed the proposals.

The Medicines and Healthcare products Regulatory Agency (MHRA) has published its response to a consultation on updating the definition of gene therapy medicinal products (GTMPs) in the Human Medicines Regulations 2012. The response appeared on 19 November 2026. The agency ran the six-week exercise jointly with Northern Ireland's Department of Health.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Official source: MHRA ↗

Article written by VigiEye from the official source (MHRA). AI-assisted; check the source before acting.